Centinel Spine®, LLC ("the Company"), the leading global medical device company focused exclusively on treating cervical and lumbar spinal disease with the most complete and clinically-proven total disc replacement (TDR) technology platform in the world (prodisc®), announced achievement of record revenue in the first quarter of 2024—outperforming Q4 2023, its previous record quarter.
Centinel Spine remains the fastest growing company in the spine industry* and is dedicated exclusively to total disc replacement, the fastest growing segment in orthopedic implants.
The Company remains well-positioned from a profitability perspective, achieving its fourth consecutive adjusted EBITDA positive quarter in Q1 2024.**
Highlights on the New Match-the-Disc™ prodisc C Vivo & prodisc C SK Cervical System
Over 5,000 procedures have been completed with the new system (since limited release in Q3 2022).
Record prodisc C Vivo and prodisc C SK revenue in Q1 2024, representing 216% YOY growth.
Added record number of new surgeons using the Match-the-Disc system in Q1 2024, increasing the total number of system users by nearly 140% YOY and almost 20% in sequential quarterly growth.
Nearly 75% of the over 600 surgeons using the Match-the-Disc system to date are repeat users and the strong majority of surgeon users come from competitive conversions.
Centinel Spine CEO Steve Murray adds, "These first quarter results show that the momentum behind our prodisc cervical and lumbar business remains strong. The company set a new revenue record in Q1 2024 while surpassing an extremely strong performance in Q4 2023. Last year was a transformative year for Centinel Spine and set the foundation for accelerated growth moving forward—as demonstrated by our Q1 2024 performance."
For more information, please visit www.CentinelSpine.com
